全文获取类型
收费全文 | 806篇 |
免费 | 38篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 43篇 |
妇产科学 | 14篇 |
基础医学 | 86篇 |
口腔科学 | 35篇 |
临床医学 | 59篇 |
内科学 | 281篇 |
皮肤病学 | 15篇 |
神经病学 | 15篇 |
特种医学 | 151篇 |
外科学 | 31篇 |
综合类 | 30篇 |
预防医学 | 44篇 |
眼科学 | 4篇 |
药学 | 22篇 |
中国医学 | 1篇 |
肿瘤学 | 18篇 |
出版年
2022年 | 2篇 |
2021年 | 12篇 |
2020年 | 6篇 |
2019年 | 5篇 |
2018年 | 7篇 |
2017年 | 4篇 |
2016年 | 6篇 |
2015年 | 11篇 |
2014年 | 23篇 |
2013年 | 18篇 |
2012年 | 15篇 |
2011年 | 20篇 |
2010年 | 30篇 |
2009年 | 37篇 |
2008年 | 37篇 |
2007年 | 21篇 |
2006年 | 26篇 |
2005年 | 19篇 |
2004年 | 19篇 |
2003年 | 26篇 |
2002年 | 21篇 |
2001年 | 27篇 |
2000年 | 22篇 |
1999年 | 31篇 |
1998年 | 31篇 |
1997年 | 38篇 |
1996年 | 46篇 |
1995年 | 30篇 |
1994年 | 26篇 |
1993年 | 35篇 |
1992年 | 11篇 |
1991年 | 15篇 |
1990年 | 17篇 |
1989年 | 14篇 |
1988年 | 16篇 |
1987年 | 22篇 |
1986年 | 23篇 |
1985年 | 9篇 |
1984年 | 7篇 |
1983年 | 4篇 |
1982年 | 18篇 |
1981年 | 6篇 |
1980年 | 7篇 |
1977年 | 9篇 |
1976年 | 7篇 |
1975年 | 7篇 |
1974年 | 2篇 |
1971年 | 1篇 |
1970年 | 1篇 |
1968年 | 1篇 |
排序方式: 共有851条查询结果,搜索用时 0 毫秒
761.
Engelstad BL; Spitler LE; Del Rio MJ; Ramos EC; Rosendorf LL; Reinhold CE; Khentigan A; Huberty JP; Corpuz SW; Lee HM 《Radiology》1986,161(2):419-422
A phase 1 study was conducted using a monoclonal antimelanoma antibody-DTPA conjugate labeled with indium-111, for immunolymphoscintigraphy in patients with metastatic melanoma. The imaging agent, labeled with 1 mCi (37 MBq) In-111, was administered as an interstitial interdigital injection to six patients scheduled to undergo lymph node dissection for suspected metastatic malignant melanoma. No adverse effects were observed in any of the patients either during or after the infusion as determined by clinical and laboratory parameters. Antibodies to the murine immunoglobulin were produced in some patients. Regional lymph nodes were visualized whether tumor-bearing or not, and light microscopic autoradiography showed In-111 activity associated with histiocytes. One of two patients harboring both tumor-bearing and tumor-free lymph nodes exhibited preferential localization in tumor-bearing nodes. The authors conclude that this study demonstrates safety of the radiopharmaceutical and that further study is needed to improve its usefulness for diagnosis of lymph node metastases. 相似文献
762.
Human immunodeficiency virus infection in tuberculosis patients 总被引:4,自引:0,他引:4
C P Theuer P C Hopewell D Elias G F Schecter G W Rutherford R E Chaisson 《The Journal of infectious diseases》1990,162(1):8-12
Human immunodeficiency virus (HIV) serology was performed in non-Asian-born patients 18-65 years old with newly diagnosed tuberculosis at a county tuberculosis clinic, and demographic and clinical features of HIV-seropositive and HIV-seronegative patients were compared. Sixty of 128 eligible patients agreed to participate, of whom 17 (28%) were seropositive. Risk of HIV was associated with homosexual contact, intravenous drug use, or both; however, 4 (24%) of the 17 seropositives denied risk behaviors. Significantly more blacks (48%) than whites (10%) or Latinos (20%) were HIV-seropositive (P less than .01). Site of disease, tuberculin reactivity, response to therapy, drug toxicity, and relapse did not differ significantly between groups. HIV-seropositive patients had significantly lower median CD4+ cell counts (326/mm3, range 23-742/mm3, vs. 929/mm3, range 145-2962/mm3, P less than .0005) and median CD4+:CD8+ ratios (0.50, range 0.14-1.07 vs. 1.54, range 0.35-4.36, P less than .0001). HIV infection is associated with clinically typical tuberculosis and HIV screening of tuberculosis patients is recommended in areas where HIV is endemic. 相似文献
763.
HIV/AIDS and antiretroviral treatment knowledge, attitudes, beliefs, and practices in HIV-infected adults in Soweto, South Africa 总被引:3,自引:0,他引:3
Nachega JB Lehman DA Hlatshwayo D Mothopeng R Chaisson RE Karstaedt AS 《Journal of acquired immune deficiency syndromes (1999)》2005,38(2):196-201
A cross-sectional study of knowledge, attitudes, beliefs, and practices (KABPs) toward HIV and antiretroviral therapy (ART) was conducted in Soweto, South Africa, using a standardized validated questionnaire. Of 105 HIV clinic patients evaluated, 70% of whom were not on ART, 89% had good knowledge about the cause of HIV infection and 83% knew about modes of transmission. Fifty-nine percent reported they were not worried about ART side effects. Sixty-five percent agreed that missing ART doses can lead to disease progression. Ninety percent had disclosed their HIV serostatus to 1 or more persons, but only 62% of those with a current sexual partner reported having told that partner. Approximately 80% reported that if they were taking ART, they would not be worried about family or friends finding out. Forty-nine percent believed that ART can cure HIV, a belief that was associated with a low level of education (P<0.001). Overall, knowledge of the cause of HIV/AIDS, modes of transmission, and importance of ART adherence was good in our study population. Further research is warranted to assess the extent to which this knowledge and attendant attitudes predict ART adherence levels. The low rate of HIV serostatus disclosure to sexual partners calls for multidimensional interventions to reduce HIV-related stigma. 相似文献
764.
765.
766.
767.
768.
769.
770.
OBJECTIVE: To describe the natural history of advanced HIV disease in patients treated with zidovudine. DESIGN: Longitudinal, observational study. SETTING: Twelve academic and community-based sites. PATIENTS, PARTICIPANTS: Eight hundred and sixty-three patients with AIDS or AIDS-related complex (ARC) with a CD4+ lymphocyte count less than 250 x 10(6)/l, who first received zidovudine between 15 April 1987 and 14 April 1988. MAIN OUTCOME MEASURES: Survival, progression to AIDS and first development of specific opportunistic illness. RESULTS: Median survival after initiation of zidovudine therapy ranged from greater than 900 days in patients with a baseline CD4+ lymphocyte count greater than or equal to 150 x 10(6)/l to 560 days in patients with a CD4+ lymphocyte count less than 50 x 10(6)/1. Other factors associated significantly with poorer survival were diagnosis of AIDS (versus ARC), baseline age greater than or equal to 40 years, hematocrit less than 35%, and diminished functional status. In patients with ARC at enrollment, median time of progression to AIDS ranged from 810 days in patients with a CD4+ lymphocyte count greater than or equal to 150 x 10(6)/l to 310 days in patients with a CD4+ lymphocyte count less than 50 x 10(6)/l. Rates of development of specific opportunistic infections or neoplasms and HIV encephalopathy were determined for different baseline CD4+ lymphocyte count ranges. Myelosuppression was significantly more common in patients with CD4+ lymphocyte counts greater than or equal to 100 x 10(6)/l. Sixty-five per cent of patients with a CD4+ lymphocyte count greater than or equal to 100 x 10(6)/l and 51% with a CD4+ lymphocyte count less than 100 x 10(6)/l continued to receive zidovudine 2 years after starting therapy. CONCLUSIONS: We describe the natural history of a cohort of patients treated with zidovudine for advanced HIV disease. These CD4+ lymphocyte count-stratified estimates of disease progression should provide prognostic information useful in the clinical management of advanced disease and the design of future studies. 相似文献